Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Expanded Access Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant (MDR) HIV-1

NCT02707861 is registered in ClinicalTrials.gov with TaiMed Biologics Inc. as lead sponsor.

NCT NCT02707861
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02707861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Expanded Access Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant (MDR) HIV-1
Lead sponsor
TaiMed Biologics Inc.
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2016
Completion date
November 30, 2018
Enrollment
79 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

hiv